Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cladribine tablets significantly reduced multiple sclerosis relapse rates for two years post-treatment. Most patients did not require new therapies, and cladribine showed a favorable safety profile.
Area Of Science
- Neurology
- Immunology
- Pharmacology
Background
- Cladribine tablets offer a unique, short-course treatment for multiple sclerosis (MS).
- Limited evidence exists on patient outcomes beyond the initial 24 months of cladribine therapy.
Purpose Of The Study
- To evaluate therapeutic choices and clinical disease activity after completing cladribine treatment for MS.
- To assess the long-term effectiveness and safety of cladribine in a real-world setting.
Main Methods
- Retrospective, multicenter study of 204 MS patients who finished a 2-year cladribine course.
- Primary outcomes: post-treatment therapeutic decisions and annualized relapse rate (ARR).
Main Results
- 75.4% of patients did not start new treatments within 12 months post-cladribine.
- Significant ARR reduction observed post-cladribine (0.07 vs. 0.82, p<0.001).
- Lymphopenia was the main adverse event; cladribine demonstrated a favorable safety profile.
Conclusions
- Cladribine is effective in reducing MS relapse rates and disability progression.
- Ocrelizumab and natalizumab are common subsequent therapies.
- Further prospective studies are needed to confirm long-term impacts.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...